The potential of lipid- and polymer-based drug delivery carriers for eradicating biofilm consortia on device-related nosocomial infections

Journal of Controlled Release

Volumn 128, Issue 1, 2008, Pages 2-22

  Tamilvanan, Shunmugaperumal ^a,b   Venkateshan, Narayanan ^b   Ludwig, Annick ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ARULMIGU KALASALINGAM COLLEGE OF PHARMACY   (India)

Author keywords

Antimicrobial agents; Biofilm; Biomaterials; Catheters; Fibrous scaffolds; Implants; Liposomes; Microspheres; Nosocomial; PLGA; Thermoreversible gels

Indexed keywords

BIOFILMS; BIOMATERIALS; BIOMEDICAL EQUIPMENT; LIPIDS; MICROSPHERES; POLYMERS;

ANTIMICROBIAL AGENTS; FIBROUS SCAFFOLDS; THERMOREVERSIBLE GELS;

DRUG DELIVERY;

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEPHALOSPORIN; CHLORHEXIDINE; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; KETOCONAZOLE; LIPID; METRONIDAZOLE; MINOCYCLINE; POLY(METHYL METHACRYLATE); POLYGLACTIN; POLYMER; RIFAMPICIN; SULFADIAZINE SILVER; TETRACYCLINE; VANCOMYCIN;

AREA UNDER THE CURVE; BIOFILM; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; HOSPITAL INFECTION; HYDROGEL; IN VITRO STUDY; NONHUMAN; PERIODONTITIS; PRIORITY JOURNAL; REVIEW; SEPTICEMIA; SUSTAINED DRUG RELEASE;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL ADHESION; BIOFILMS; CROSS INFECTION; DRUG CARRIERS; EQUIPMENT AND SUPPLIES; HUMANS; LIPIDS; LIPOSOMES; POLYMERS;

EID: 42749084975     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.01.006     Document Type: Review

References (254)

1. Tenke P., Kovacs B., Jäckel M., and Nagy E. The role of biofilm infection in urology. World J. Urol. 24 (2006) 13-20
2. Vinh D.C., and Embil J.M. Device-related infections: a review. J. Long Term Eff. Med. Implants 15 (2005) 467-488
3. Rutala W.A., and Weber D.J. Use of inorganic hypochlorite (bleach) in health-care facilities. Clin. Microbiol. Rev. 10 (1997) 597-610
4. Anaissie E., Penzak S., and Dignani C. The hospital water supply as a source of nosocomial infections. Arch. Intern. Med. 162 (2002) 1483-1492
5. Cozad A., and Jones R.D. Disinfection and the prevention of infectious disease. Am. J. Infect. Control. 31 (2003) 243-254
6. Sehulster L., and Chinn R.Y.W. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Centers for Disease Control and Prevention. M.M.W.R. Recomm. Rep. 52 RR-10 (2003) 1-42
7. Brady M.J., Lisay C.M., Yurkovetskiy A.V., and Sawan S.P. Persistent silver disinfectant for the environmental control of pathogenic bacteria. Am. J. Infect. Control. 31 (2003) 208-214
8. Richards M.J., Edwards J.R., Culver D.H., and Gaynes R.P. Nosocomial infections in medical intensive care units in the United States National Nosocomial Infections Surveillance System. Crit. Care Med. 27 (1999) 887-892
9. Costerton J.W., Montanaro L., and Arciola C.R. Biofilm in implant infections: its production and regulation. Int. J. Artif. Organs 28 (2005) 1062-1068
10. Gorman S.P., and Jones D.S. Complications of urinary devices. In: Wilson M. (Ed). Medical Implications of Biofilms (2003), Cambridge University Press, Cambridge 136-170
11. Keane P.F., Bonner M.C., Johnston S.R., Zafar A., and Gorman S.P. Characterization of biofilm and encrustation on ureteral stents in vivo. Br. J. Urol. 73 (1994) 687-691
12. Tunney M.M., Jones D.S., and Gorman S.P. Assessment of biofilm and biofilm-related problems associated with urinary tract devices. In: Doyle R.J. (Ed). Methods in Enzymology: Biofilms (1998), Academic Press, Florida 558-566
13. Malcolm R.K., McCullagh S.D., Woolfson A.D., Gorman S.P., Jones D.S., and Cuddy J. Controlled release of a model antibacterial drug from a novel self-lubricating silicone biomaterial. J. Control. Rel. 97 (2004) 313-320
14. Jones D.S., Garvin C.P., Dowling D., Donnelly K., and Gorman S.P. Examination of surface properties and in vitro biological performance of amorphous diamond-like carbon-coated polyurethane. J. Biomed. Mater. Res. Part B: Appl. Biomater. 78B (2006) 230-236
15. Matthew A., Myer B., and Rushton N. In vitro and in vivo investigations into the biocompatibility of diamond-like carbon (DLC) coatings for orthopedic applications. J. Biomed. Mater. Res. 58 (2001) 319-328
16. Jones M.I., McColl R., Grant D.M., Parker K.G., and Parker T.L. Protein adsorption and platelet attachment and activation, on TiN, TiC, and DLC coatings on titanium for cardiovascular applications. J. Biomed. Mater. Res. 52 (2000) 413-421
17. Dowling D.P., Donnelly K., and O'Brien T.P. Application of diamond like carbon films as hermetic coatings on optical fibres. Diamond Relat. Mater. 5 (1996) 492-495
18. Duran L.W. Preventing medical device related infections. Med. Device Technol. 11 6 (2000) 14-17
19. Stiver H.G., Zachidniak Z., and Speert D.P. Inhibition of polymorphonuclear leucocyte chemotaxis by the mucoid exopolysaccharide of P. aeruginosa. Clin. Invest. Med. 11 (1988) 247-252
20. Costerton J.W. Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin. Orthop. Relat. Res. 437 (2005) 7-11
21. Fitzpatrick F., Humphreys H., and O'Gara J.P. The genetics of staphylococcal biofilm formation-will a greater understanding of pathogenesis lead to better management of device-related infection?. Clin. Microbiol. Infect. 11 (2005) 967-973
22. Smith A.W. Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems?. Adv. Drug Del. Rev. 57 (2005) 1539-1550
23. von Eiff C., Jansen B., Kohnen W., and Becker K. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs 65 (2005) 179-214
24. Reisnera A., Høibyb N., Tolker-Nielsena T., and Molina S. Microbial pathogenesis and biofilm development. In: Russell W., and Herwald H. (Eds). Concepts in Bacterial Virulence. Contrib. Microbiol. vol. 12 (2005), Karger, Basel 114-131
25. Hall-Stoodley L., Costerton J.W., and Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2 (2004) 95-108
26. Donlan R.M. Biofilms: microbial life on surfaces. Emerg. Infect. Dis. 8 (2002) 881-890
27. Sihorkar V., and Vyas S.P. Biofilm consortia on biomedical and biological surfaces: delivery and targeting strategies. Pharm. Res. 18 (2001) 1247-1254
28. McCrory R., Jones D.S., Adair C.G., and Gorman S.P. Pharmaceutical strategies to prevent ventilator-associated pneumonia. J. Pharm. Pharmacol. 55 (2003) 411-428
29. Gristina A.G. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science 237 (1987) 1588-1595
30. Kuhn D.M., George T., Chandra J., Mukherjee P.K., and Ghannoum M.A. Antifungal susceptibility of candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46 (2002) 1773-1780
31. Doggett M.S. Characterization of fungal biofilms within a municipal water distribution system. Appl. Environ. Microbiol. 66 (2000) 1249-1251
32. Brown M.R., and Barker J. Unexplored reservoirs of pathogenic bacteria: protozoa and biofilms. Trends Microbiol. 7 (1999) 46-50
33. Khardori N., and Yassien M. Biofilms in device related infections. J. Ind. Microbiol. 15 (1995) 141-147
34. Hindupur S., and Muslin A.J. Septic shock induced from an implantable cardioverter-defibrillator lead-associated Candida albicans vegetation. J. Interv. Card. Electrophysiol. 14 (2005) 55-59
35. Kojic E.M., and Darouiche R.O. Candida infections of medical devices. Clin. Microbiol. Rev. 17 (2004) 255-267
36. Hall-Stoodley L., Costerton J.W., and Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2 (2004) 95-108
37. Lewis K. The riddle of biofilm resistance. Antimicrob. Agents Chemother. 45 (2001) 999-1007
38. Dobretsov S., Dahms H.U., and Qian P.Y. Inhibition of biofouling by marine microorganisms and their metabolites. Biofouling 22 (2006) 43-54
39. Coetser S.E., and Cloete T.E. Biofouling and biocorrosion in industrial water systems. Crit. Rev. Microbiol. 31 (2005) 213-232
40. Yan T., and Yan W.X. Fouling of offshore structures in China-a review. Biofouling Suppl. 1 (2003) 133-138
41. Fux C.A., Stoodley P., Hall-Stoodley L., and Costerton J.W. Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev. Anti-Infect. Ther. 1 (2003) 667-683
42. Stewart P.S., and Costerton J.W. Antibiotic resistance of bacteria in biofilms. Lancet 358 (2001) 135-138
43. Lindsay D., and von Holy A. Bacterial biofilms within the clinical setting: what healthcare professionals should know. J. Hosp. Infect. 64 (2006) 313-325
44. Mehta A. Say no to nosocomial infections. Express Pharma. (March 16-31 2007) 76-78
45. Lewis K. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5 (2007) 48-56
46. Fux C.A., Costerton J.W., Stewart P.S., and Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol. 13 (2005) 34-40
47. Davies D. Understanding biofilm resistance to antibacterial agents. Nat. Rev. Drug Discov. 2 (2005) 114-122
48. Sutherland I.W. The biofilm matrix-an immobilised but dynamic environment. Trends Microbiol. 9 (2001) 222-227
49. Anderl J.N., Franklin M.J., and Stewart P.S. Role of antibiotic penetration limitation of Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob. Agents Chemother. 44 (2000) 1818-1824
50. O'Grady N.P., Alexander M., Dellinger E.P., Gerberding J.L., Heard S.O., Maki D.G., Masur H., McCormick R.D., Mermel L.A., Pearson M.L., Raad I.I., Randolph A., and Weinstein R.A. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm. Rep. 51 RR-10 (2002) 1-29
51. Domenico P., Baldassarri L., Schoch P.E., Kaehler K., Sasatsu M., and Cunha B.A. Activities of bismuth thiols against staphylococci and staphylococcal biofilms. Antimicrob. Agents Chemother. 45 (2001) 1417-1421
52. Ahearn D.G., Grace D.T., Jennings M.J., Borazjani R.N., Boles K.J., Rose L.J., Simmons R.B., and Ahanotu E.N. Effects of hydrogel/silver coatings on in vitro adhesion to catheters of bacteria associated with urinary tract infection. Curr. Microbiol. 41 (2000) 120-125
53. Darouiche R.O., Raad I.I., Heard S.O., Thornby J.I., Wenker O.C., Gabrielli A., Berg J., Khardori N., Hanna H., Hachem R., Harris R.L., and Mayhall G. A comparison of two antimicrobial-impregnated central venous catheters. New Engl. J. Med. 340 (1999) 1-8
54. Johnson J.R., Delavari P., and Azar M. Activities of a nitrofurazone containing urinary catheter and a silver hydrogel catheter against multidrug resistant bacteria characteristic of catheter-associated urinary tract infection. Antimicrob. Agents Chemother. 43 (1999) 2990-2995
55. Stickler D.J. Bacterial biofilms and the encrustation of urethral catheters. Biofouling 94 (1996) 293-305
56. Sobho F., Khoury A.E., Zamboni A.C., Davidson D., and Mittelman M.W. Effects of ciprofloxacin and protamine sulfate combinations against catheter-associated Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 39 (1995) 1281-1286
57. Flowers R.H., Schwenzer K.J., Kopel R.F., Fish M.J., Tucker S.I., and Farr B.M. Efficacy of an attachable subcutaneous cuff for the prevention of intravascular catheter-related infection. A randomized controlled trial. JAMA 261 (1989) 878-883
58. Burton E., Gawande P.V., Yakandawala N., LoVetri K., Zhanel G.G., Romeo T., Friesen A.D., and Madhyastha S. Antibiofilm activity of GlmU enzyme inhibitors against catheter-associated uropathogens. Antimicrob. Agents Chemother. 50 (2006) 1835-1840
59. Pickering S.A.W., Bayston R., and Scanlin T.F. Electromagnetic augmentation of antibiotic efficacy in infection of orthopaedic implants. J. Bone Jt. Surg. BR 85B (2003) 588-593
60. Stewart P.S., Wattanakaroon W., Goodrum L., Fortun S.M., and McLeod B.R. Electrolytic generation of oxygen partially explains electrical enhancement of tobramycin efficacy against Pseudomonas aeruginosa biofilm. Antimicrob. Agents Chemother. 43 (1999) 292-296
61. Raad I., Hachem R., Zermeno A., Stephens L.C., and Bodey G.P. Silver iontophoretic catheter: a prototype of a long-term antiinfective vascular access device. J. Infect. Dis. 173 (1996) 495-498
62. Costerton J.W., Ellis B., Lam K., Johnson F., and Khoury A.E. Mechanism of electrical enhancement of efficacy of antibiotics in killing biofilm bacteria. Antimicrob. Agents Chemother. 38 (1994) 2803-2809
63. Carmen J.C., Nelson J.L., Beckstead B.L., Runyan C.M., Robison R.A., Schaap A.P., and Pitt W.G. Ultrasonic-enhanced gentamicin transport through colony biofilms of Pseudomonas aeruginosa and Escherichia coli. J. Infect. Dis. 10 (2004) 193-199
64. Carmen J.C., Roeder B.L., Nelson J.L., Beckstead B.L., Runyan C.M., Schaalje G.B., Robison R.A., and Pitt W.G. Ultrasonically enhanced vancomycin activity against Staphylococcus epidermidis biofilms in vivo. J. Biomater. Appl. 18 (2004) 237-245
65. Pitt W.G., and Ross S.A. Ultrasound increases the rate of bacterial growth. Biotechnol. Prog. 19 (2003) 1038-1044
66. Rediske A.M., Roeder B.L., Nelson J.L., Robison R.L., Schaalje G.B., and Robison R.A. Pulsed ultrasound enhances the killing of Escherichia coli biofilms by aminoglycoside antibiotics in vivo. Antimicrob. Agents Chemother. 44 (2000) 771-772
67. Gad F., Zahra T., Hasan T., and Hamblin M.R. Effects of growth phase and extracellular slime on photodynamic inactivation of gram-positive pathogenic bacteria. Antimicrob. Agents Chemother. 48 (2000) 2173-2178
68. Wainwright M., and Crossley K.B. Photosensitising agents-circumventing resistance and breaking down biofilms: a review. Int. Biodeterior. Biodegrad. 53 (2004) 119-126
69. O'Neill J.F., Hope C.K., and Wilson M. Oral bacteria in multispecies biofilms can be killed by red light in the presence of toluidine blue. Lasers Surg. Med. 31 (2002) 86-90
70. Soukos N.S., Socransky S.S., Mulholland S.E., Lee S., and Doukas A.G. Photomechanical drug delivery into bacterial biofilms. Pharm. Res. 17 (2000) 405-409
71. Kabanov A., Batrakova E., and Alakhov V. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control Rel. 82 (2002) 189-212
72. Gilles D., Jean G., Florence A., and Jean C. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm. Res. 23 (2006) 2709-2728
73. Nace V. Nonionic Surfactants: Polyoxyalkylene Block Copolymers (1996), Marcel Dekker, New York
74. Catuogno C., and Jones M.N. The antibacterial properties of solid supported liposomes on Streptococcus oralis biofilms. Int. J. Pharm. 257 (2003) 125-140
75. DiTizio V., Ferguson G.W., Mittelman M.W., Khoury A.E., Bruce A.W., and DiCosmo F. A liposomal hydrogel for the prevention of bacterial adhesion to catheters. Biomaterials 19 (1998) 1877-1884
76. Kim J.H., Gias M., and Jones M.N. The adsorption of cationic liposomes to Staphylococcus aureus biofilms. Colloids Surf. A Physicochem. Eng. Asp. 149 (1999) 561-570
77. Jones M.N., Song Y.H., Kaszuba M., and Reboiras M.D. The interaction of phospholipid liposomes with bacteria and their use in the delivery of bactericides. J. Drug Target 5 (1997) 25-34
78. Pinto-Alphandary H., Andremont A., and Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and implications. Int. J. Antimicrob. Agents 13 (2000) 155-168
79. Nightingale S.D., Saletan S.L., Swenson C.E., Lawrence A.J., Watson D.A., Pilkiewicz F.G., Silverman E.G., and Cal S.X. Liposome encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients. Antimicrob. Agents Chemother. 37 (1993) 1869-1872
80. Majumdar S., Flasher D., Friend D.S., Nassos P., Yajko D., Hadley W.K., and Duzgunes N. Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-Mycobacterium intracellulare complex infections in human peripheral blood monocyte/macrophages. Antimicrob. Agents Chemother. 36 (1992) 2808-2815
81. Eduardo L., Bermudez M., Wu M., and Young L.S. Intracellular killing of Mycobacterium avium complex by rifapentine and liposome encapsulated Amikacin. J. Infect. Dis. 156 (1987) 510-513
82. Fountain M.W., Weiss S.J., Fountain A.G., Shen A., and Lenk R.P. Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides. J. Infect. Dis. 152 (1985) 529-535
83. Lin J., Qui S., Lewis K., and Klibanov A.M. Bactericidal properties of flat surfaces and nanoparticles derivatized with alkylated polyethylenimines. Biotechnol. Prog. 18 (2002) 1082-1086
84. Donelli G., Francolini I., Piozzi A., Di Rosa R., and Marconi W. New polymer-antibiotic systems to inhibit bacterial biofilm formation: a suitable approach to prevent central venous catheter-associated infections. J. Chemother. 14 (2002) 501-507
85. Bach A., Eberhardt H., Frick A., Schmidt H., Bottinger B.W., and Martin E. Efficacy of silver-coating central venous catheters in reducing bacterial colonization. Crit. Care Med. 27 (1999) 515-520
86. Schierholz J.M., Lucas L.J., Rump A., and Pulverer G. Efficacy of silver-coated medical devices. J. Hosp. Infect. 40 (1998) 257-262
87. Sheretz R.J., Carruth W.A., Hampton A.A., Byron M.P., and Solomon D.D. Efficacy of antibiotic-coated catheters in preventing subcutaneous Staphylococcus aureus infection. J. Infect. Dis. 167 (1993) 98-106
88. Tebbs S.E., and Elliott T.S.J. A novel antimicrobial central venous catheter impregnated with benzalkonium chloride. J. Antimicrob. Chemother. 31 (1993) 261-271
89. Donelli G., and Francolini I. Efficacy of antiadhesive, antibiotic and antiseptic coatings in preventing catheter-related infections: review. J. Chemother. 13 (2001) 595-606
90. Danese P.N. Antibiofilm approaches: prevention of catheter colonization. Chem. Biol. 9 (2002) 873-880
91. Rachid S., Ohlsen K., Witte W., Hacker J., and Ziebuhr W. Effect of subinhibitory antibiotic concentrations on polysaccharide intercellular adhesin expression in biofilm-forming Staphylococcus epidermidis. Antimicrob. Agents Chemother. 44 (2000) 3357-3363
92. Finelli A., Burrows L.L., DiCosmo F.A., DiTizio V., Sinnadurai S., Oreopoulos D.G., and Khoury A.E. Colonization-resistant antimicrobial-coated peritoneal dialysis catheters: evaluation in a newly developed rat model of persistent Pseudomonas aeruginosa peritonitis. Perit. Dial. Int. 22 1 (2002) 27-31
93. Pugach J.L., DiTizio V., Mittelman M.W., Bruce A.W., DiCosmo F., and Khoury A.E. Antibiotic hydrogel coated Foley catheters for prevention of urinary tract infection in a rabbit model. J. Urol. 162 (1999) 883-887
94. Johnson J.R., Kuskowski M.A., and Wilt T.J. Systematic review: antimicrobial urinary catheters to prevent catheter-associated urinary tract infection in hospitalized patients. Ann. of Intern. Med. 144 2 (2006) 116-126
95. Srinivasan A., Karchmer T., Richards A., Song X., and Perl T.M. A prospective trial of a novel, silicone-based, silver-coated foley catheter for the prevention of nosocomial urinary tract infections. Infect. Control Hosp. Epidemiol. 27 1 (2006) 38-43
96. Ahmed K., Gribbon P.N., and Jones M.N. The application of confocal microscopy to the study of liposome adsorption onto bacterial biofilms. J. Liposome Res. 12 4 (2002) 285-300
97. Jones M.N. Use of liposomes to deliver bactericides to bacterial biofilms. Methods Enzymol. 391 (2005) 211-228
98. Kim H.J., and Jones M.N. The delivery of benzyl penicillin to Staphylococcus aureus biofilms by use of liposomes. J. Liposome Res. 14 3-4 (2004) 123-139
99. Ahmed K., and Jones M.N. The effect of shear on the desorption of liposomes adsorbed to bacterial biofilms. J. Liposome Res. 13 2 (2003) 187-197
100. Ahmed K., Muiruri P.W., Jones G.H., Scott M.J., and Jones M.N. The effect of grafted poly(ethylene glycol) on the electrophoretic properties of phospholipid liposomes and their adsorption to bacterial biofilms. Colloids Surf A Physicochem. Eng. Asp. 194 (2001) 287-296
101. Robinson A.M., Bannister M., Creeth J.E., and Jones M.N. The interaction of phospholipid liposomes with mixed bacterial biofilms and their use in the delivery of bactericide. Colloids Surf A Physicochem. Eng. Asp. 186 (2001) 43-53
102. Hill K.J., Kaszuba M., Creeth J.E., and Jones M.N. Reactive liposomes encapsulating a glucose oxidase-peroxidase system with antibacterial activity. Biochim. Biophys. Acta Biomembr. 1326 (1997) 37-46
103. Donowitz G.R. Tissue directed antibiotics and intracellular parasites: complex interactions of phagocytes, pathogens and drugs. Clin. Infect. Dis. 19 (1994) 926-930
104. al-Orainey I.O., Bashandi A.M., and Saeed E.N. Failure of ciprofloxacin to eradicate brucellosis in experimental animals. J. Chemother. 2 (1990) 380-383
105. Raoult M.M. Optimum treatment of intracellular infection. Drugs 52 (1996) 45-59
106. Holmes B., Quie P.G., Windhorst D.B., Pollara B., and Good R.A. Protection of phagocytized bacteria from the killing action of antibiotics. Nature 11 (1966) 1131-1133
107. Rous P., and Jones F.S. The protection of pathogenic microorganisms by living tissue cells. J. Exp. Med. 23 (1916) 601-605
108. van den Broek P.J. Antimicrobial drugs, microorganisms, and phagocytes. Rev. Infect. Dis. 11 (1989) 213-245
109. Salem I.I., Flasher D.L., and Düzgüneş N. Liposome-encapsulated antibiotics. Methods Enzymol. 391 Spec. Iss. (2005) 261-291
110. Gupta C.M., and Haq W. Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections. Methods Enzymol. 391 Spec. Iss. (2005) 291-304
111. Kuhlmann J., Schaefer H.G., and Beermann D. Clinical pharmacology. In: Kuhlmann J., Dalhoff A., and Zeiler H.J. (Eds). Quinolone Antibacterials. Handbook of Experimental Pharmacology vol. 127 (1998), Springer-Verlag, Berlin 339-406
112. Nix D.E., Goodwin D., Peloquin C.A., Rotella D.L., and Schentag J.J. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob. Agents Chemother. 35 (1991) 1947-1950
113. Dalhoff A. A review of quinolone pharmacokinetics. In: Fernandes P.B. (Ed). Telesymposium on Quinolones (1989), J. R. Prous. Science Publishers, Barcelona, Spain 277-312
114. Bergan T., Dalhoff A., and Rohwedder R. Pharmacokinetics of ciprofloxacin. Infection 16 Suppl. 1 (1988) 3-13
115. Easmon C.S.F., and Crane J.P. Uptake of ciprofloxacin by macrophages. J. Clin. Pathol. 38 (1985) 442-444
116. Easmon C.C.F., and Crane J.P. Uptake of ciprofloxacin by human neutrophils. J. Antimicrob. Chemother. 16 (1985) 67-73
117. Rastogi N., and Blom Potar M.C. Intracellular bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis H37Rv multiplying in the J-775 macrophage cell line. Zbl. Bakt. 273 (1990) 195-199
118. Hanan M.S., Riad E.M., and el-Khouly N.A. Antibacterial efficacy and pharmacokinetic studies of ciprofloxacin on Pasteurella multocida infected rabbits. Dtsch. Tierarztl. Wochenschr. 107 (2000) 151-155
119. Wong J.P., Yuang H., Blasetti K.L., Schnell G., Conley J., and Schofield L.N. Liposome delivery of ciprofloxacin against Francisella tularensis infection. J. Control Rel. 92 (2003) 265-273
120. Ellbogen M.H., Olsen K.M., Gentry-Nielsen M.J., and Preheim L.C. Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J. Antimicrob. Chemother. 51 (2003) 83-91
121. Cordeiro C., Wiseman D.L., Lutwyche P., Uh M., Evans J.C., Finlay B.B., and Webb M.S. Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar typhimurium intracellular infection model. Antimicrob. Agents Chemother. 44 (2000) 533-539
122. Semple S.C., Chonn A., and Cullis P.R. Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behavior in vivo. Adv. Drug Deliv. Rev. 32 (1998) 3-17
123. Senior J., Trimble K.R., and Maskiewicz R. Interaction of positively-charged liposomes with blood: implications for their application in vivo. Biochim. Biophys. Acta. 1070 (1991) 173-179
124. Oku N., Tokudome Y., Namba Y., Saito N., Endo M., Hasegawa Y., Kawai M., Tsukada H., and Okda S. Effect of serum protein binding on real-time trafficking of liposomes with different charges analyzed by positron emission tomography. Biochim. Biophys. Acta. 1280 (1996) 149-154
125. Hernandez-Caselles T., Villalain J., and Gomez-Fernandez J.C. Influence of liposome charge and composition on their interaction with human blood serum proteins. Mol. Cell Biochem. 120 (1993) 119-126
126. Chonn A., Semple S.C., and Cullis P.R. Protein-membrane interactions in the biological milieu. In: Op den Kamp J.A.F. (Ed). Biological Membranes: Structure, Biogenesis and Dynamics NATO ASI Series H: Cell Biology vol. 82 (1994) 101-109
127. Oja C.D., Semple S.C., Chonn A., and Cullis P.R. Influence of dose on liposome clearance: critical role of blood proteins. Biochim. Biophys. Acta. 1281 (1996) 31-37
128. Allen T.M., Hancen C., Martin F., Redemann C., and Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta. 1066 (1991) 29-36
129. Klibanov A.L., Maruyama K., Torchilin V.P., and Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268 (1990) 235-237
130. Bakker-Woudenberg I.A.J.M., Schiffelers R.M., ten Kate M.T., Storm G., Guo L., and Working P. Targeting of antibiotics in bacterial infection using pegylated long-circulating liposomes. J. Liposome. Res. 10 (2000) 513-521
131. Bakker-Woudenberg I.A.J.M., ten Kate M.T., Guo L., Working P., and Mouton J.W. Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob. Agents Chemother. 45 (2001) 1487-1492
132. Bakker-Woudenberg I.A.J.M., ten Kate M.T., Guo L., Working P., and Mouton J.W. Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. Antimicrob. Agents Chemother. 46 8 (2002) 2575-2581
133. Parsons C.L., Boychuk D., Jones S., Hurst R., and Callahan H. Bladder surface glycosaminoglycans: an epithelial permeability barrier. J. Urol. 143 (1990) 139-142
134. Mysorekar I.U., and Hultgren S.J. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc. Natl. Acad. Sci. 103 (2006) 14170-14175
135. Wright K.J., Seed P.C., and Hultgren S.J. Uropathogenic Escherichia coli flagella aid in efficient urinary tract colonization. Infect. Immun. 73 (2005) 7657-7668
136. Christensen D., Korsholm K.S., Rosenkrands I., Lindenstrøm T., Andersen P., and Agger E.M. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 6 (2007) 785-796
137. Sapra P., and Allen T.M. Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res. 42 (2003) 439-462
138. Tauber A.L., Borregaard N., Simon E., and Wright J. Chronic granulomatous disease: a syndrome of phagocyte oxidase deficiencies. Medicine 62 (1963) 286
139. Winkelstein J.A., Marino M.C., Johnston Jr. R.B., Boyle J., Cumutte J., Gallin J.I., Malech H.L., Holland S.M., Ochs H., Quie P., Buckley R.H., Foster C.B., and Chanock S.J. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine 79 (2000) 155-169
140. Gallin J.I. Recent advances in chronic glaucomatous disease. Ann. Intern. Med. 99 (1983) 657-674
141. Sloan J.M., Cameron C.H., Maxwell R.J., McCluskey D.R., and Collins J.S. Colitis complicating chronic granulomatous disease. A clinicopathological case report. Gut 38 (1996) 619-622
142. McDermott R.P. Inflammatory bowel disease. Curr. Opin. Gastroenterol. 10 (1994) 355-357
143. Al-Mobaireek K.F. Ulcerative colitis and chronic granulomatous disease: a case report and review of the literature. Saudi J. Gastroenterol. 7 (2001) 119-121
144. Freiberg S., and Zhu X.X. Polymer microspheres for controlled drug release. Int. J. Pharm. 282 (2004) 1-18
145. Varde N.K., and Pack D.W. Microspheres for controlled drug delivery. Expert Opin. Biol. Ther. 4 (2004) 35-51
146. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3 (2004) 785-796
147. Moses M.A., Brem H., and Langer R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell 4 (2003) 337-341
148. Sinha V.R., and Trehan A. Biodegradable microspheres for protein delivery. J. Control Rel. 90 (2003) 261-280
149. Zhao Z., Wang J., Mao H.Q., and Leong K.W. Polyphosphoesters in drug and gene delivery. Adv. Drug Deliv. Rev. 55 (2003) 483-499
150. Stemberger A., Grimm H., Bader F., Rahn H.D., and Ascherl R. Local treatment of bone and soft tissue infections with the collagen-gentamicin sponge. Eur. J. Surg. 578 (1997) 17-26
151. Keogh B.S., Triplett R.G., Aufdemorte T.B., and Boyan B.D. The effect of local antibiotics in treating chronic osseous Staphylococcus aureus infection. J. Oral Maxillofac Surg. 47 (1989) 940-945
152. Kanellakopoulou K., Kolia M., Anastassiadis A., Korakis T., Giamarellous-Bourboulis E.J., Andreopoulos A., Dounis E., and Giamarellou H. Lactic acid polymers as biodegradable carriers of fluoroquinolones: an in vitro study. Antimicrob. Agents Chemother. 43 (1999) 714-716
153. Mader J.T., Calhoun J., and Cobos J. In vitro evaluation of antibiotic diffusion from antibiotic-impregnated biodegradable beads and polymethylmetacrylate beads. Antimicrob. Agents Chemother. 41 (1997) 415-418
154. Zhang X., Wyss U.P., Pichora D., and Goosen M.F. Biodegradable controlled antibiotic release devices for osteomyelitis: optimization of release properties. J. Pharm. Pharmacol. 46 (1994) 718-724
155. Wei G., Kotoura Y., Oka M., Yamamuro T., Wada R., Hyon S.-H., and Ikada Y. A bioabsorbable delivery system for antibiotic treatment of osteomyelitis. J. Bone Jt. Surg. 73 (1991) 246-252
156. Ambrose C.G., Gogola G.R., Clyburn T.A., Raymond A.K., Peng A.S., and Mikos A.G. Antibiotic microspheres: preliminary testing for potential treatment of osteomyelitis. Clin. Orthop. 415 (2003) 279-285
157. Overbeck J.P., Winckler S.T., Meffert R., Törmälä P., Spiegel H.U., and Brug E. Penetration of ciprofloxacin into bone: a new bioabsorbable implant. J. Invest. Surg. 8 (1995) 155-162
158. Nie L., Nicolau D.P., Nightingale C.H., Browner B.D., and Quintiliani R. In vitro elution of ofloxacin from a bioabsorbable polymer. Acta. Orthop. Scand 66 (1995) 365-368
159. Garvin K.L., Miyano J.A., Robinson D., Giger D., Novak J., and Radio S. Polylactide/polyglycolide antibiotic implants in the treatment of osteomyelitis. J. Bone Joint Surg. 76 (1994) 1500-1506
160. Jacob E., Setterstrom J.A., Bach D.E., Heath III J.R., McNiesh L.M., and Cienry III G. Evaluation of biodegradable ampicillin anhydrate microcapsules for local treatment of experimental staphylococcal osteomyelitis. Clin. Orthop. 267 (1991) 237-244
161. Le Rey A.M., Chiffoleau S., Iooss P., Grimandi G., Gouyette A., Daculsi A., and Merle C. Vancomycin encapsulation in biodegradable poly(ε-caprolactone) microparticles for bone implantation. Influence of the formulation process on size, drug loading, in vitro release and cytocompatibility. Biomaterials 24 (2003) 443-449
162. Burd T.A., Anglen J.O., Lowry K.J., Hendricks K.J., and Day D. In vitro elution characteristics of tobramycin from bioabsorbable polycaprolactone bead. J. Orthop. Trauma 15 (2001) 424-428
163. Hendricks K.J., Lane D.L., Burd T.A., Lowry K.J., Day D., Phaup J.G., and Anglen J.O. Elution characteristics of tobramycin from polycaprolactone in a rabbit model. Clin. Orthop. 392 (2001) 418-426
164. Solberg B.D., Gutow A.P., and Baumgaertner M.R. Efficacy of gentamycin-impregnated resorbable hydroxyapatite cement in treating osteomyelitis in a rat model. J. Orthop. Trauma 13 (1999) 102-106
165. Gerhart T.N., Roux R.F., Horowitz G., Miller R.L., Hanff P., and Hayes W.C. Antibiotic release from an experimental biodegradable bone cement. J. Orthop. Res. 6 (1988) 585-592
166. Mäkinen T.J., Veiranto M., Lankinen P., Moritz N., Jalava J., Törmälä P., and Aro H.T. In vitro and in vivo release of ciprofloxacin from osteoconductive bone defect filler. J. Antimicrob. Chemother. 56 (2005) 1063-1068
167. Shirtliff M.E., Calhoun J.H., and Mader J.T. Experimental osteomyelitis treatment with antibiotic-impregnated hydroxyapatite. Clin. Orthop. 401 (2002) 239-247
168. Saito T., Takeuchi R., Hirakawa K., Nagata N., Yoshida T., Koshino T., Okuda K., Takema M., and Hori T. Slow-releasing potential of vancomycin-loaded porous hydroxyapatite blocks implanted into MRSA osteomyelitis. J. Biomed. Mater Res. 63 (2002) 245-251
169. Nolan P.C., Wilson D.J., and Mollan R.A. Calcium hydroxyapatite ceramic delivery system. J. Bone Jt. Surg. 75 (1993) 600-604
170. Nelson C.L., McLaren S.G., Skinner R.A., Smeltzer M.S., Thomas J.R., and Olsen K.M. The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets. J. Orthop. Res. 20 (2002) 643-647
171. Mader J.T., Stevens C.M., Stevens J.H., Roble R., Lathrop J.T., and Calhoun J.H. Treatment of experimental osteomyelitis with a fibrin sealant antibiotic implant. Clin. Orthop. 403 (2002) 58-72
172. McKee M.D., Wild L.M., Schemitsch E.H., and Waddell J.P. The use of an antibiotic-impregnated, osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects: early results of a prospective trial. J. Orthop. Trauma 16 (2002) 622-627
173. Holtom P.D., and Patzakis M.J. Newer methods of antimicrobial delivery for bone and joint infections. Instr. Course Lect. 52 (2003) 745-749
174. Chen J.F., and Lee S.T. Antibiotic-polymethylmethacrylate strut: an option for treating cervical pyogenic spondylitis, Case report. J. Neurosurg. Spine 5 1 (2006) 90-95
175. Nelson C.L., Hickmon S.G., and Harrison B.H. Elution characteristics of gentamicin-PMMA beads after implantation in humans. Orthopedics 17 5 (1994) 415-416
176. Hettfleisch J., and Schottle H. Local preventive antibiotic treatment in intramedullary nailing with gentamycin impregnated biomaterials. Aktuelle Traumatol 23 2 (1993) 68-71
177. Letsch R., Rosenthal E., and Joka T. Local antibiotic administration in osteomyelitis treatment-a comparative study with two different carrier substances. Aktuelle Traumatol. 23 7 (1993) 324-329
178. Schmidmaier G., Lucke M., Wildemann B., Haas N.P., and Raschke M. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury Int. J. Care Injured 37 (2006) S105-S112
179. Bauer T.W., and Schils J. The pathology of total joint arthroplasty. I. Mechanisms of implant fixation. Skeletal Radiol. 28 8 (1999) 423-432
180. Taylor G.J., Bannister G.C., and Calder S. Perioperative wound infection in elective orthopaedic surgery [published erratum appears in J. Hosp. Infect. 1991 Feb; 17(2):155]. J. Hosp. Infect. 16 3 (1990) 241-247
181. Eron L.J. Prevention of infection following orthopedic surgery. Antibiot. Chemother. 33 (1985) 140-164
182. Koort J.K., Suokas E., Veiranto M., Mäkinen T.J., Jalava J., Törmälä P., and Aro H.T. In vitro and in vivo testing of bioabsorbable antibiotic containing bone filler for osteomyelitis treatment. J. Biomed. Mater Res. 78A (2006) 532-540
183. Kanellalopoulou K., and Giamarellos-Bourboulis E.J. Carrier systems for the local delivery of antibiotics in bone infections. Drugs 59 (2000) 1223-1232
184. Castro C., Sánchez E., Delgado A., Soriano I., Núńez P., Baro M., Perera A., and Évora C. Ciprofloxacin implants for bone infection. In vitro-in vivo characterization. J. Control. Rel. 93 (2003) 341-354
185. Yenice I., Çalis S., Atilla B., Kas H.S., Ozalp M., Ekizoglu M., Bilgili H., and Hincal A.A. In vitro/in vivo evaluation of the efficiency of teicoplanin-loaded biodegradable microparticles formulated for implantation to infected bone defects. J. Microencapsul. 20 (2003) 705-717
186. Yenice I., Çalis S., Kas H.S., Ozalp M., Ekizoglu M., and Hincal A.A. Biodegradable implantable teicoplanin beads for the treatment of bone infections. Int. J. Pharm. 242 (2002) 271-275
187. Gursel I., Yagmurlu F., Korkusuz F., and Hasirci V. In vitro antibiotic release from poly(3hydroxybutyrate-co-3-hydroxyvalerate) rods. J. Microencapsul. 19 (2002) 153-164
188. Hasegawa M., Sudo A., Komlev V.S., Barinov S.M., and Uchida A. High release of antibiotic from a novel hydroxyapatite with bimodal pore size distribution. J. Biomed. Mater Res. 70B (2004) 332-339
189. Yoo J.Y., Kim J.M., Khang G., Kim M.S., Cho S.H., Lee H.B., and Kim Y.S. Effect of lactide/glycolide monomers on release behaviours of gentamicin sulfate-loaded PLGA discs. Int. J. Pharm. 276 (2004) 1-9
190. Kim K., Luu Y.K., Chang C., Fang D., Hsiao B.S., Chu B., and Hadjiargyrou M. Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds. J. Control Rel. 98 (2004) 47-56
191. Schlapp M., and Friess W. Collagen/PLGA microparticle controlled composites for local delivery of gentamicin. J. Pharm. Sci. 92 (2003) 2145-2151
192. Heasman P.A., and Seymour R.A. Pharmacological control of periodontal disease I. Antiplaque agents. J. Dent. 22 (1994) 323-335
193. Gordon J.M., and Walker C.B. Current status of systemic antibiotic usage in destructive periodontal disease. J. Periodontal. 64 (1993) 760-771
194. Pandit J.K. Targeted devices for periodontal diseases. In: Jain N.K. (Ed). Controlled Drug Delivery (1997), CBS Publishers and distributors, New Delhi, India 130-146
195. Kelly H.M., Deasy P.B., Ziaka E., and Claffey N. Formulation and preliminary in vivo dog studies of a novel drug delivery system for the treatment of periodontitis. Int. J. Pharm. 274 (2004) 167-183
196. Schwach-Abdellaoni K., Vivien-Castioni N., and Gurny R. Local delivery of antimicrobial agents for the treatment of periodontal diseases. Eur. J. Pharm. Biopharm. 50 (2000) 83-99
197. Ahuja A., Ali J., and Rahman S. Biodegradable periodontal intrapocket device containing metronidazole and amoxycillin: formulation and characterisation. Pharmazie 61 (2006) 25-29
198. Veyries M.L., Couarraze G., Geiger S., Agnely F., Massias L., and Kunzli B. Controlled release of vancomycin from poloxamer 407 gels. Int. J. Pharm. 192 (1999) 183-193
199. Esposito E., Carotta V., Scabbia A., Trombelli L.D., Antona P., and Menegatti E. Comparative analysis of tetracycline-containing dental gels: poloxamer- and monoglyceride-based formulations. Int. J. Pharm. 142 (1996) 9-23
200. Miyazaki S., Tobiyama T., Takada M., and Attwood D. Percutaneous absorption of indomethacin from pluronic F 127 gels in rats. J. Pharm. Pharmacol. 47 (1995) 455-457
201. Lee S.H., Lee J.E., Baek W.Y., and Lim J.O. Regional delivery of vancomycin using pluronic F-127 to inhibit methicillin resistance Staphylococcus aureus (MRSA) growth in chronic otitis media in vitro and in vivo. J. Control Rel. 96 (2004) 1-7
202. Bridgett M.J., Davies M.C., and Denyer S.P. Control of staphylococcal adhesion to polystyrene surfaces by polymer surface modification with surfactants. Biomaterials 13 7 (1992) 411-416
203. Desai N.P., Hossainy S.F., and Hubbell J.A. Surface-immobilized polyethylene oxide for bacterial repellence. Biomaterials 13 7 (1992) 417-420
204. Dunkirk S.G., Gregg S.L., Duran L.W., Monfils J.D., Haapala J.E., Marcy J.A., Clapper D.L., Amos R.A., and Gurie P.E. Photochemical coatings for the prevention of bacterial colonization. J. Biomater. Appl. 6 2 (1991) 131-156
205. Tebbs S.E., Sawyer A., and Elliott T.S. Influence of surface morphology on in vitro bacterial adherence to central venous catheters. Br. J. Anaesth. 72 5 (1994) 587-591
206. Tebbs S.E., and Elliott T.S. Modification of central venous catheter polymers to prevent in vitro microbial colonization. Eur. J. Clin. Microbiol. Infect. Dis. 13 2 (1994) 111-117
207. Jansen B., Schareina S., Steinhauser H., et al. Development of polymers with antiinfective properties. Polym. Mater. Sci. Eng. 57 (1987) 43-46
208. Baumgartner J.N., Yang C.Z., and Cooper S.L. Physical property of analysis and bacterial adhesion on a series of phosphonated polyurethanes. Biomaterials 18 2 (1997) 831-837
209. Kohnen W., and Jansen B. Changing material surface chemistry for preventing bacterial adhesion. In: An Y.H., and Friedman R.J. (Eds). Handbook of Bacterial Adhesion (2000), Humana Press, Totowa (NJ) 581-589
210. An Y.H., Blair B.K., Martin K.L., et al. Macromolecule surface coating for preventing bacterial adhesion. In: An Y.H., and Friedman R.J. (Eds). Handbook of Bacterial Adhesion (2000), Humana Press, Totowa (NJ) 609-625
211. Solovskij M.V., Ulbrich K., and Kopecek J. Synthesis of N-(2-hydroxypropyl)methacrylamide copolymers with antimicrobial activity. Biomaterials 4 1 (1983) 44-48
212. Jansen B., and Peters G. Modern strategies in the prevention of polymer-associated infections. J. Hosp. Infect. 19 2 (1991) 83-88
213. Jansen B., Jansen S., Peters G., and Pulverer G. In vitro efficacy of a central venous catheter ('Hydrocath') loaded with teicoplanin to prevent bacterial colonization. J. Hosp. Infect. 22 2 (1992) 93-107
214. Romano G., Berti M., Goldstein B.P., and Borghi A. Efficacy of a central venous catheter ('Hydrocath') loaded with teicoplanin in preventing subcutaneous staphylococcal infection in the mouse. Zentral Bakteriol. 279 3 (1993) 426-433
215. Jansen B., and Kohnen W. Prevention of biofilm formation by polymer modification. J. Ind. Microbiol. 15 4 (1995) 391-396
216. Kamal G.D., Pfaller M.A., Rempe L.E., and Jebson P.J. Reduced intravascular catheter infection by antibiotic bonding: a prospective, randomized, controlled trial. JAMA 265 18 (1991) 2364-2368
217. Maki D.G., Weise C.E., and Sarafin H.W. A semiquantitative culture method for identifying intravenous-catheter-related infection. N. Engl. J. Med. 296 23 (1977) 1305-1309
218. Kamal G.D., Divishek D., Kumar G.C., Porter B.R., Tatman D.J., and Adams J.R. Reduced intravascular catheter-related infection by routine use of antibiotic-bonded catheters in a surgical intensive care unit. Diagn. Microbiol. Infect. Dis. 30 3 (1998) 145-152
219. Raad I., Darouiche R., Hachem R., Sacilowski M., and Bodey G.P. Antibiotics and prevention of microbial colonization of catheters. Antimicrob. Agents Chemother. 39 11 (1995) 2397-2400
220. Raad I., Darouiche R., Hachem R., Mansouri M., and Bodey G.P. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampicin. J. Infect. Dis. 173 2 (1996) 418-424
221. Raad I., Darouiche R., Dupuis J., Abi-Said D., Gabrielli A., Hachem R., Wall M., Harris R., Jones J., Buzaid A., Robertson C., Shenaq S., Curling P., Burke T., and Ericsson C. Central venous catheters coated with minocycline and rifampicin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial, The Texas Medical Center Catheter Study Group. Ann. Intern. Med. 127 4 (1997) 267-274
222. Crnich C.J., and Maki D.G. The promise of novel technology for the prevention of intravascular device-related bloodstream infection, I: pathogenesis and short-term devices. Clin. Infect. Dis. 34 9 (2002) 1232-1242
223. Tambe S.M., Sampath L., and Modak S.M. In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. J. Antimicrob. Chemother. 47 5 (2001) 589-598
224. Schierholz J.M., Fleck C., Beuth J., and Pulverer G. The antimicrobial efficacy of a new central venous catheter with long-term broad-spectrum activity. J. Antimicrob. Chemother. 46 1 (2000) 45-50
225. Kingston D., Seal D.V., and Hill I.D. Self-dispersing plastics for intravenous catheters and prosthetic inserts. J. Hyg. (Lond.) 96 2 (1986) 185-198
226. Quesnel L.B., Al Najjar A.R., and Buddhavudhikrai P. Synergism between chlorhexidine and sulfadiazine. J. Appl. Bacteriol. 45 3 (1978) 397-405
227. Heard S.O., Wagle M., Vijayakumar E., McClean S., Brueggemann A., Napolitano L.M., Edwards L.P., O'Connell F.M., Puyana J.C., and Doern G.V. Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch. Intern. Med. 158 1 (1998) 81-87
228. Bach A., Schmidt H., Bottiger B., Schreiber B., Bohrer H., Motsch J., Martin E., and Sonntag H.G. Retention of antibacterial activity and bacterial colonisation of antiseptic-bonded central venous catheters. J. Antimicrob. Chemother. 37 2 (1996) 315-322
229. Hannan M., Juste R.N., Umasankar S., Glendenning A., Nightingale C., Azadian B., and Soni N. Antiseptic-bonded central venous catheters and bacterial colonisation. Anaesthesia 54 9 (1999) 868-872
230. Ciresi D.L., Albrecht R.M., Volkers P.A., and Scholten D.J. Failure of antiseptic bonding to prevent central venous catheter-related infection and sepsis. Am. Surg. 62 8 (1996) 641-646
231. Pemberton L.B., Ross V., Cuddy P., Kremer H., Fessler T., and McGurk E. No difference in catheter sepsis between standard and antiseptic central venous catheters: a prospective randomized trial. Arch. Surg. 131 9 (1996) 986-989
232. George S.J., Vuddamalay P., and Boscoe M.J. Antiseptic-impregnated central venous catheters reduce the incidence of bacterial colonization and associated infection in immunocompromised transplant patients. Eur. J. Anaesthesiol. 14 4 (1997) 428-431
233. Logghe C., Van Ossel C., D'Hoore W., Ezzedine H., Wauters G., and Haxhe J.J. Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: a randomized controlled trial. J. Hosp. Infect. 37 2 (1997) 145-156
234. Maki D.G., Stolz S.M., Wheeler S., and Mermel L.A. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled trial. Ann. Intern. Med. 127 4 (1997) 257-266
235. Tennenberg S., Lieser M., McCurdy B., Boomer G., Howington E., Newman C., and Wolf I. A prospective randomized trial of an antibiotic- and antiseptic-coated central venous catheter in the prevention of catheter-related infections. Arch. Surg. 132 12 (1997) 1348-1351
236. Collin G.R. Decreasing catheter colonization through the use of an antiseptic-impregnated catheter: a continuous quality improvement project. Chest 115 6 (1999) 1632-1640
237. Sheng W.H., Ko W.J., Wang J.T., Chang S.C., Hsueh P.R., and Luh K.T. Evaluation of antiseptic-impregnated central venous catheters for prevention of catheter-related infection in intensive care unit patients. Diagn. Microbiol. Infect. Dis. 38 1 (2000) 1-5
238. Brun-Buisson C., Doyon F., Sollet J.P., Cochard J.F., Cohen Y., and Nitenberg G. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver-sulfadiazine-coated catheters. Intensive Care Med. 30 (2004) 837-843
239. Tattawasart U., Maillard J.Y., Furr J.R., and Russell A.D. Development of resistance to chlorhexidine diacetate and cetylpyridinium chloride in Pseudomonas stutzeri and changes in antibiotic susceptibility. J. Hosp. Infect. 42 3 (1999) 219-229
240. Oda T., Hamasaki J., Kanda N., and Mikami K. Anaphylactic shock induced by an antiseptic-coated central venous [correction of nervous] catheter [published erratum appears in Anesthesiology 1998 Feb 88 (2): 560]. Anesthesiology 87 5 (1997) 1242-1244
241. Gosheger G., Hardes J., Ahrens H., Streitburger A., Buerger H., Erren M., Gunsel A., Kemper F.H., Winkelmann W., and Von Eiff C. Silver-coated megaendoprostheses in a rabbit model: an analysis of the infection rate and toxicological side effect. Biomaterials 25 24 (2004) 5547-5556
242. Sioshansi P. New processes for surface treatment of catheters. Artif. Organs 18 4 (1994) 266-271
243. Mclean R.J., Hussain A.A., Sayer M., Vincent P.J., Hughes D.J., and Smith T.J. Antibacterial activity of multilayer silver-copper surface film on catheter material. Can. J. Microbiol. 39 9 (1993) 895-899
244. Davenas J., Thevenard P., Philippe F., and Arnaud M.N. Surface implantation treatments to prevent infection complications in short term devices. Biomol. Eng. 19 2-6 (2002) 263-268
245. Gatter N., Kohnen W., and Jansen B. In vitro efficacy of hydrophilic central venous catheter loaded with silver to prevent microbial colonization. Zentralbl Bakteriol. 287 1-2 (1998) 157-169
246. Jansen B., Rinck M., Wolbring P., Strohmeier A., and Jahns T. In vitro evaluation of the antimicrobial efficacy and biocompatibility of a silver-coated central venous catheter. J. Biomater. Appl. 9 1 (1994) 55-70
247. Böswald M., Lugauer S., Regenfus A., Braun G.G., Martus P., Geis C., Scharf J., Bechert T., Greil J., and Guggenbichler J.P. Reduced rates of catheter-associated infection by use of a new silver-impregnated central venous catheter. Infection 27 Suppl. 1 (1999) S56-S60
248. Ranucci M., Isgro G., Giomarelli P.P., Pavesi M., Luzzani A., Cattabriga I., Carli M., Giomi P., Compostella A., Digito A., Mangani V., Silvestri V., Mondelli E., and Catheter Related Infection Trial (CRIT) Group. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit. Care Med. 31 1 (2003) 52-59
249. Liu W.K., Tebbs S.E., Byrne P.O., and Elliott T.S. The effect of electric current on bacteria colonising intravenous catheters. J. Infect. 27 3 (1993) 261-269
250. Raad I., Hachem R., Zermeno A., Dumo M., and Bodey G.P. In vitro antimicrobial efficacy of silver iontophoretic catheter. Biomaterials 17 11 (1996) 1055-1059
251. Goldschmidt H., Hahn U., Salwender H.J., Haas R., Jansen B., Wolbring P., Rinck M., and Hunstein W. Prevention of catheter-related infection by silver coated central venous catheter in oncological patients. Zentralbl Bakteriol. 283 2 (Dec. 1995) 215-223
252. Carbon R.T., Lugauer S., Geitner U., Regenfus A., Böswald M., Greil J., Bechert T., Simon S.I., Hümmer H.P., and Guggenbichler J.P. Reducing catheter associated infections with silver-impregnated catheters in long-term therapy of children. Infection 27 Suppl. 1 (1999) S69-S73
253. Stoiser B., Kofler J., Staudinger T., Georgopoulos A., Lugauer S., Guggenbichler J.P., Burgmann H., and Frass M. Contamination of central venous catheters in Immunocompromised patients; a comparison between two different types of central venous catheters. J. Hosp. Infect. 50 3 (Mar 2002) 202-206
254. Beech I.B., Sunner J.A., and Hiraoka K. Microbe-surface interactions in biofouling and biocorrosion processes. Inter. Microbiol. 8 (2005) 157-168